Sensus Healthcare, Inc. (NASDAQ:SRTS) Receives $8.00 Consensus Price Target from Analysts

Sensus Healthcare, Inc. (NASDAQ:SRTS) has been given an average recommendation of “Hold” by the five ratings firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $8.00.

Several research firms recently weighed in on SRTS. Zacks Research raised shares of Sensus Healthcare from a “strong sell” rating to a “hold” rating in a report on Wednesday, October 22nd. Wall Street Zen upgraded shares of Sensus Healthcare from a “sell” rating to a “hold” rating in a research report on Saturday, December 20th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Sensus Healthcare in a report on Thursday, January 22nd.

Insiders Place Their Bets

In other news, Director Eric Sachetta purchased 7,000 shares of the stock in a transaction dated Friday, November 21st. The shares were bought at an average cost of $3.93 per share, for a total transaction of $27,510.00. Following the transaction, the director owned 140,113 shares in the company, valued at $550,644.09. This trade represents a 5.26% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Joseph C. Sardano acquired 25,000 shares of the business’s stock in a transaction dated Tuesday, November 18th. The stock was purchased at an average price of $4.03 per share, with a total value of $100,750.00. Following the acquisition, the chief executive officer owned 1,200,293 shares of the company’s stock, valued at approximately $4,837,180.79. This trade represents a 2.13% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have acquired 35,500 shares of company stock valued at $143,310. 8.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Sensus Healthcare

Hedge funds have recently made changes to their positions in the business. Pacific Ridge Capital Partners LLC lifted its stake in Sensus Healthcare by 21.8% during the fourth quarter. Pacific Ridge Capital Partners LLC now owns 698,634 shares of the company’s stock valued at $2,781,000 after purchasing an additional 125,245 shares during the last quarter. Divisadero Street Capital Management LP increased its holdings in shares of Sensus Healthcare by 39.5% in the third quarter. Divisadero Street Capital Management LP now owns 452,897 shares of the company’s stock valued at $1,422,000 after buying an additional 128,224 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Sensus Healthcare by 3.5% during the 4th quarter. Geode Capital Management LLC now owns 158,240 shares of the company’s stock valued at $630,000 after acquiring an additional 5,316 shares during the last quarter. Sachetta LLC boosted its stake in shares of Sensus Healthcare by 6.8% during the 4th quarter. Sachetta LLC now owns 148,508 shares of the company’s stock worth $591,000 after acquiring an additional 9,500 shares in the last quarter. Finally, Evernest Financial Advisors LLC acquired a new position in shares of Sensus Healthcare in the 2nd quarter worth $255,000. Institutional investors and hedge funds own 25.30% of the company’s stock.

Sensus Healthcare Trading Down 2.6%

SRTS opened at $4.91 on Thursday. The business’s 50 day moving average is $4.42 and its 200-day moving average is $3.93. The stock has a market cap of $80.62 million, a PE ratio of -25.84 and a beta of 1.21. Sensus Healthcare has a twelve month low of $3.03 and a twelve month high of $6.35.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.